Hippocampal Functional Connectivity Index for Alzheimer's Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and measuring the progression of Alzheimer's disease, such as cognitive tests and imaging techniques, are inadequate for early detection and distinguishing between dementia caused by Alzheimer's and other factors, and are not sensitive enough to identify mild cognitive impairment (MCI) patients who may develop Alzheimer's disease.
Innovation Solution
A method and system that improves the identification of brain regions affected by Alzheimer's disease by using fMRI to measure functional connectivity, specifically by employing memory tasks to stimulate BOLD responses in the hippocampal region and calculating a Phase Delay Index (PDI) to enhance sensitivity and signal-to-noise ratio, allowing for more precise voxel selection and connectivity index calculation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional fMRI methods are used to detect Alzheimer's disease, then structural changes can be observed, but the method lacks sensitivity to distinguish Alzheimer's-related dementia from other causes and cannot detect mild cognitive impairment
Solution Approach 1:
The patent changes the measurement parameter from structural imaging to functional connectivity analysis using Phase Delay Index. By measuring the phase delay between BOLD signals in different hippocampal regions during memory tasks, the method achieves higher sensitivity in detecting Alzheimer's-related functional disruptions without requiring complex structural segmentation, thus resolving the contradiction between detection sensitivity and method complexity
Solution Approach 2:
The patent replaces structural measurement approaches with functional signal analysis. Instead of measuring physical structural changes in the hippocampus, the method uses fMRI BOLD signal phase relationships to detect functional connectivity disruptions, achieving superior detection sensitivity while maintaining relatively simple implementation
2Measurement precision
If cognitive tests are used to measure brain function, then brain function can be assessed, but the method cannot distinguish between dementia caused by Alzheimer's disease and dementia caused by other factors
Solution Approach 1:
The patent introduces functional connectivity measurement as an intermediary between cognitive tests and disease diagnosis. By measuring the phase delay in BOLD signals between hippocampal regions during memory tasks, the method provides objective physiological evidence that distinguishes Alzheimer's-related dementia from other causes, while maintaining testing efficiency through automated fMRI analysis
Solution Approach 2:
The patent replaces subjective cognitive testing with objective functional imaging measurement. Instead of relying on patient performance in cognitive tasks that can be influenced by non-Alzheimer's factors, the method directly measures hippocampal functional connectivity disruptions using fMRI phase delay analysis, achieving superior disease differentiation accuracy
3Measurement precision
If structural imaging methods are used to assess brain changes, then structural alterations can be detected, but profound structural changes can occur without cognitive impairment or symptoms being evident
Solution Approach 1:
The patent performs preliminary functional assessment before cognitive symptoms manifest. By measuring hippocampal functional connectivity and phase delay relationships during memory tasks, the method detects early functional disruptions that precede cognitive impairment, enabling early intervention while maintaining correlation with eventual symptom development
Solution Approach 2:
The patent replaces structural measurement with functional measurement to maintain better correlation with cognitive status. By measuring BOLD signal phase relationships during actual memory task performance, the method ensures that detected abnormalities are functionally relevant and likely to correlate with cognitive symptoms, avoiding false positives from structurally altered but functionally normal tissue
4Measurement precision
If PET and SPECT are used to monitor regional cerebral glucose metabolism and blood flow, then functional connectivity can be assessed, but the clinical utility is still controversial despite frequent reports of abnormal function
Solution Approach 1:
The patent replaces PET/SPECT radiotracer-based measurement with fMRI BOLD signal measurement. By using endogenous blood oxygenation changes during memory tasks, the method achieves comparable functional connectivity assessment without the controversies surrounding radiotracer interpretation, improving clinical utility consistency through more direct measurement of task-related neural activity
Solution Approach 2:
The patent changes the measurement parameter from metabolic rate or blood flow to BOLD signal phase delay. This parameter change provides more direct information about functional connectivity timing and synchronization in the hippocampus during memory tasks, resolving the controversy by providing clearer, more interpretable functional abnormalities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables more accurate identification of Alzheimer's disease progression and mild cognitive impairment, improving the sensitivity of connectivity index measurements and providing a tool for early detection and monitoring of brain disorders.
Implementation Method 1
Conventional fMRI detects changes in cerebral blood volume, flow, and oxygenation that locally occur in association with increased neuronal activity induced by functional paradigms
Data Source
AI summary
Time course MRI data is acquired from the hippocampal region of the brain and processed to produce two indices that are a measure of the functional connectivity between locations therein. The MRI data is acquired while the brain is substantially at rest and the spontaneous low frequency component of the time course data at each location in the hippocampus is extracted and compared in a cross-correlation process. Also acquired is fMRI data which indicates those locations in the brain that should be included in the index calculations.